PHARMACIST

May 7 2020

#Top #80 #pharmaceutical #companies-Top 80 pharmaceutical companies



Top 100 pharmaceutical companies

Pharmaceutical Industry Market Research & Statistics

  • Currently 3 /5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5

119 votes

Major sectors under Pharmaceutical

More market segments:

Global Pharmaceuticals Industry

The global pharmaceutical industry is a highly competitive industry that should be worth more than $1 trillion in 2014, marking a 5% compound annual growth rate reports analysts from Urch Publishing. The industry is comprised of companies that make, patent and sell drugs that have therapeutic effect. The market is highly competitive and entry is difficult due to a combination of strict regulation and the need for extensive research and development involving time consuming clinical trials.

In addition, high research and development costs, lengthy clinical trial processes, expiring patents and difficulty in gaining product approval from the appropriate regulatory bodies all mean that companies must produce blockbuster drugs and continue to do so to remain in good standing. Other challenges facing the industry include pressure from purchasers such as hospitals, who negotiate discounts with wholesalers or manufacturers when buying in bulk – thereby increasing pressure on pharmaceutical companies to produce cost-effective drugs to remain competitive and gain approval for new drugs. According to the Center for Drug Evaluation and Research, on average there have been less than 23 approvals annually over the past decade. Industry observer Pharmalot states there was a fall in the number of applications for approval received by the US Food and Drug Administration from just fewer than 40 in 2009 to 23 in 2010.

Though patents protect the intellectual property rights of specific drugs, usually for approximately 20 years, pharmaceutical companies face increasing pressure related to generics, which are drugs comprised of the same ingredients as patented drugs but sold under a drug’s chemical name rather than the pharmaceutical brand name. Medical professionals can prescribe drugs under their chemical name without specifying a brand. The pharmaceutical market spans a spectrum of drugs and medication, including prescription, generic and over-the-counter drugs. The scope also includes drug delivery technology, drug discovery and development, vitamins and supplements, pathology, therapeutics, and pharmacies and drug stores.

Leading Pharmaceutical Market Segments

The US is at the top of the global pharmaceutical market and is expected to hit almost $345 billion in 2014 according to Datamonitor. The US is seconded by the Japanese market, which is followed by the EU.

However, according to research by the International Federation of Pharmaceutical Wholesalers (IFPW), there are significant disparities between growth rates in developed and emerging markets based on their capacity to bounce back from the economic crisis. The latter includes 17 countries, which Intercontinental Marketing Services divides into three segments. The first includes only China for which analysts predict will become the third-largest pharmaceutical market in the world in 2011, with a forecast $40 billion increase by 2013 matching US market growth. Datamonitor predicts the pharmaceutical market in China will reach almost $49 billion in 2015. Market growth in China is being fuelled by rising cases of chronic diseases, an aging population and increased healthcare investment and insurance.

The second segment of emerging pharmaceutical markets includes Brazil, India and Russia, which together are predicted to increase between $5 billion and $15 billion by 2013. The third segment is comprised of Mexico, Venezuela, Argentina, Turkey, Poland, Thailand, Indonesia, Vietnam, Egypt, South Africa, Pakistan, the Ukraine, and Romania.

All segments combined represent 17 emerging pharmaceutical markets predicted to grow at a rate of around 16% in 2011 to reach between $170-$180 billion largely due to an increase in healthcare spending by government, private and public bodies, according to IFPW research.

Within developed markets, IFPW forecasts around a 6% growth rate, far lower than emerging market growth in 2011. Even lower growth rates are predicted in Europe where the top five markets, namely the UK, France, Spain, Italy and Germany, are forecast to grow at around 2%.

Market growth rate in the US is expected to grow at around 4%, reaching between $320 billion and $330 billion. Elsewhere, Brazil is predicted to be worth almost $35 billion in 2015, reports Datamonitor.

Industry Leaders

Datamonitor lists the top 10 industry leaders as Pfizer, Hoffman-La Roche, Novartis, GlaxoSmithKline, Aventis, Sanofi-Aventis, AstraZeneca, Abbott laboratories, Merck & Co and Bristol-Myers Squibb Company.

Headquartered in New York, Pfizer has over 110,000 employees and is the leading research-based pharmaceutical company worldwide. Pfizer reported a 36% rise in revenues in 2010 reaching almost $68 billion, up from $50 billion the previous year, largely thanks to its acquisition of competitor Wyeth, which Pfizer purchased for $68 billion. Pfizer manufactures the 2010 number-one selling prescription drug in the US, Lipitor. Sales for Lipitor reached $7.2 billion in 2010 and represented 18% of the company’s biopharmaceutical revenue. Lipitor is used to treat patients with raised levels of cholesterol.

Pfizer also acquired King Pharmaceuticals in 2010 at a cost of $3.6 billion. King manufactures various medications for use in pain management, a market worth $22 billion. King products that will likely boost Pfizer sales include Embeda and Remoxy, which are painkillers that pose less risk of addiction than other offerings on the market. Emeda sales for the six-month period following its launch reached sales of almost $24 million.

Swiss-based Novartis was established in 1996 with the merger of Sandoz and Ciba-Geigy. Among its well-known drugs are Gleevic, used in the treatment of chronic myeloid leukemia. In one of its initiatives, Novartis supplied Gleevic to 27,000 patients spanning 80 countries. In 2010, Novartis’s Gilenya was approved in the US by the FDA, and in Russia and Switzerland. Gilenya is the first oral treatment used in the treatment of relapse-remitting multiple sclerosis. In the second quarter of 2011, Novartis saw its net sales grow 27% to almost $15 billion. Its core operating income increased 29% to $4.2 billion.

AstraZeneca, a leader in the pharmaceutical market, was established in 1999 with the merger of UK based Zeneca Group and Swiss Astra AB. The company has 61,000 employees across 100 countries, with almost half of them in the US and Africa, Asia and Australasia. The EU accounts for 46% of its workforce. AstraZeneca invests more than $4 billion annually in research and development and has 14 research centers in eight countries worldwide. The company’s sales for 2010 reached $33 billion. In 2011 it saw product liability lawsuits put a dent in its profits, having to put aside almost $650 million to settle over 28,000 lawsuits concerning its drug Seroquel. Claimants allege that Seroquel, an antipsychotic used in the treatment of bipolar disease and schizophrenia, may cause diabetes in some users. The company is involved in the manufacture and/or distribution of over 93 drugs in the US, 9 of which were among the top 200 drugs sales in the US in 2010, reports Drugs.com.

Outlook

The market for pharmaceutical goods is increasing due to an aging global population, advances in drug-based treatment research, increased investment in healthcare and consumer-driven private health cover, and rising numbers of patients suffering from cardiovascular disease, cancer and degenerative diseases. Market growth faces particular challenges such as price pressures, strict regulation, lawsuits and expiring patents.

Aside from lawsuits faced by AstraZeneca mentioned above, there are many other cases of costly legal settlements, which are an unavoidable course of business in the pharmaceutical industry. Also, expiring patents are paving the way for generic drugs to produce cheaper versions of blockbuster drugs, cutting into pharmaceutical company profits. Many leading drugs on the market are to see their patents expire over the next five years. According to industry reports, the patents for 10 top selling drugs will expire by 2013; namely, they are Lipitor, Plavix, Seroquel, Actos, Enbrel, Singulair, Levaquin, Zyprexa, Concerta and Protonix.

Top 100 pharmaceutical companies



Top 100 pharmaceutical companies

Top 100 pharmaceutical companies

Pharmaceutical Industry Market Research & Statistics Currently 3 /5 Stars. 1 2 3 4 5 119 votes Major sectors under Pharmaceutical More market segments:
SOURCE: Top 100 pharmaceutical companies http://www.reportlinker.com/ci02257/Pharmaceutical.html Top 100 pharmaceutical companies

USA News. American News.

News latest news news today news headlines breaking news new current news world news top news latest news today,

headline news online news today's news headlines daily news local news breaking news today new news to day news recent news latest news headlines top news today top news stories news stories national news international.

News news update current news today today's national news news updates headlines news update today latest breaking news breaking news headlines latestnews latest national news english news latest world news latest,

news update latest news headlines for today hot news today headlines today news websites current news events the news today's news headlines in english current news headlines top news headlines national news headlines top.
Headlines latest headlines newspaper headlines today latest it news top stories current news stories news sites.

Written by admin